Keyword: Sandoz

Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening.

Novartis investors' discontent with first-quarter results shows how much they're expecting of new CEO Vas Narasimhan.

Sandoz may have to wait a little longer for a clear shot at launching a biosimilar to Amgen's anti-inflammatory blockbuster Enbrel.

Thursday was a busy day for Europe’s regulators—and their whirl of activity will send several drugmakers into the weekend happy.

In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis products.

Sources have told Reuters that Novartis is preparing to auction off its U.S. generics pills business.

A recently released FDA document shows that Pfizer's troubled fill-finish plant in Kansas was cited for continuing to repeat mistakes already cited by the FDA.

Novartis’ copycat arm, Sandoz, needed a win. And it got a key one Tuesday with the approval of generic 40-mg Copaxone.

Novartis has started the clock ticking for some of the 450 employees at a Colorado plant which it is closing as part of its generics consolidation.